


AMENDMENTS TO THE CLAIMS

1-74. (Canceled)

75. (Currently amended) A method of inhibiting Raf kinase activity in a human or animal subject suffering from a Ras/mitogen-activated protein kinase signal pathway-mediated cancer disorder selected from the group consisting of melanoma, breast cancer, prostate cancer, lung cancer, pancreatic cancer, thyroid cancer, bladder cancer, colon cancer, liver cancer, myeloid leukemia, and villous colon adenoma, comprising administering to the human or animal subject a composition comprising an amount of a compound of the formula (II) effective to inhibit Raf kinase activity in the human or animal subject:



(II)

wherein Y is O;

A₁ is substituted monocyclic carbocyclic aryl;

A₂ is ~~unsubstituted heteroaryl~~ pyridyl;

R₁ is taken together with R₂ to form a substituted C₃₋₁₄ heteroaryl group, wherein the C₃₋₁₄ heteroaryl group contains only carbon and nitrogen atoms as ring atoms; wherein, the dashed line represents a single or double bond;

R₃ is hydrogen; and


R₄ is C₁₋₆ alkyl;

or a pharmaceutically acceptable salt thereof.

76. (Previously presented) The method of claim 75 which further comprises administering to the human or animal subject at least one additional agent for the treatment of cancer selected from irinotecan, topotecan, gemcitabine, 5-fluorouracil, leucovorin, carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab and trastuzumab.

77. (Canceled)

78. (Currently amended) A method of inhibiting Raf kinase activity in a human or animal subject suffering from a Ras/mitogen-activated protein kinase signal pathway-mediated hormone dependent cancer disorder selected from the group consisting of breast cancer and prostate cancer, comprising administering to the human or animal subject a composition comprising an amount of a compound of the formula (II) effective to inhibit Raf kinase activity in the human or animal subject:



(II)

wherein Y is O;

A₁ is substituted monocyclic carbocyclic aryl;

A₂ is ~~unsubstituted heteroaryl~~ pyridyl;

R₁ is taken together with R₂ to form a substituted C₃₋₁₄ heteroaryl group, wherein the C₃₋₁₄ heteroaryl group contains only carbon and nitrogen atoms as ring atoms; wherein, the dashed line represents a single or double bond;

R₃ is hydrogen; and

R₄ is C₁₋₆ alkyl;


or a pharmaceutically acceptable salt thereof.

79. (Canceled)

80. (Previously presented) The method of claim 78 which further comprises administering to the human or animal subject at least one additional agent for the treatment of cancer selected from irinotecan, topotecan, gemcitabine, 5-fluorouracil, leucovorin, carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab and trastuzumab.

81. (Canceled)

82. (Currently amended) A method of inhibiting Raf kinase activity in a human or animal subject suffering from a Ras/mitogen-activated protein kinase signal pathway-mediated hematological cancer disorder, comprising administering to the human or animal subject a composition comprising an amount of a compound of the formula (II) effective to inhibit Raf kinase activity in the human or animal subject:



(II)

wherein Y is O;

A₁ is substituted monocyclic carbocyclic aryl;

A₂ is ~~unsubstituted heteroaryl~~ pyridyl;

R₁ is taken together with R₂ to form a substituted C₃₋₁₄ heteroaryl group, wherein the C₃₋₁₄ heteroaryl group contains only carbon and nitrogen atoms as ring atoms; wherein, the dashed line represents a single or double bond;

R₃ is hydrogen; and

R₄ is C₁₋₆ alkyl;

or a pharmaceutically acceptable salt thereof.

83. (Previously presented) The method of claim 82 which further comprises administering to the human or animal subject at least one additional agent for the treatment of cancer selected from irinotecan, topotecan, gemcitabine, 5-fluorouracil, leucovorin, carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab and trastuzumab.

84-88. (Canceled)

89. (Currently amended) The method of ~~claim 88~~ any one of claims 75, 76, 78, 80, 82, or 83, wherein R₄ in formula (II) is methyl.

90-92. (Canceled)

93. (Previously presented) A method of any one of claims 75, 76, 78, 80, 82, or 83, wherein A₁ in formula (II) is selected from the group consisting of chlorophenyl, fluorophenyl, bromophenyl, iodophenyl, dihalophenyl, nitrophenyl, 4-bromophenyl, 4-chlorophenyl, alkoxyphenyl, dialkoxyphenyl, dialkylphenyl, trialkylphenyl, alkylthiophenyl, trifluoromethylphenyl, acetylphenyl, sulfamoylphenyl, biphenyl, cyclohexylphenyl, phenyloxyphenyl, dialkylaminophenyl, alkylbromophenyl, alkylchlorophenyl, alkylfluorophenyl, trifluoromethylchlorophenyl, trifluoromethylbromophenyl, trifluorophenyl,


(trifluoromethyl)thiophenyl, alkoxybiphenyl, hydroxyphenyl, hydroxyalkylphenyl, 4-amino(imino)methylphenyl and (1,4'-bipiperidin-1'-ylcarbonyl)phenyl.

94. (Previously presented) The method of claim 93, wherein A₁ in formula (II) is 4-bromophenyl.

95. (Previously presented) The method of claim 93, wherein A₁ in formula (II) is trifluoromethylchlorophenyl.

96-97. (Canceled)

98. (Currently amended) The method of ~~claim 96~~ any one of claims 75, 76, 78, 80, 82, or 83, wherein A₂ in formula (II) is



99. (Canceled)

100. (Currently amended) A method of any one of claims 75, 76, 78, 80, 82, or 83, wherein R₁ is taken together with R₂ in formula (II) to form a group selected from substituted pyridyl, pyrimidinyl, ~~thiazolyl~~, indolyl, imidazolyl, ~~oxadiazolyl~~, tetrazolyl, pyrazinyl, triazolyl, ~~thiophenyl~~, furanyl, quinolinyl, purinyl, ~~benzothiazolyl~~, benzopyridyl and benzoimidazolyl.

101. (Currently amended) A method of ~~any one of claims 75, 76, 78, 80, 82, or 83~~ claim 100, wherein R₁ is taken together with R₂ in formula (II) to form a substituted imidazolyl group.

102. (Previously presented) The method of claim 100, wherein the imidazolyl group is substituted with a halo C₁₋₆ alkyl group.

103. (Previously presented) The method of claim 100, wherein the imidazolyl group is substituted with a trifluoromethyl group.

104-107. (Canceled)

108. (Previously presented) The method of claim 75, wherein the cancer is melanoma.

109. (Previously presented) The method of claim 75, wherein the cancer is a carcinoma of the lungs, pancreas, thyroid, bladder or colon.

110. (Previously presented) The method of claim 75, wherein the cancer is myeloid leukemia.

111. (Previously presented) The method of claim 75, wherein the cancer is villous colon adenoma.

112. (Previously presented) The method of claim 82 wherein the hematological cancer disorder is chronic myelogenous leukemia.

113. (Currently amended) The method of any one of claims 75, 76, 78, 80, 82, or 83, wherein A₁ in formula (II) is selected from the group consisting of ~~phenylalkyl, pyridylalkyl, pyrimidinylalkyl,~~ heterocyclylcarbonylphenyl, heterocyclylphenyl, heterocyclylalkylphenyl, chlorophenyl, fluorophenyl, bromophenyl, iodophenyl, dihalophenyl, nitrophenyl, 4-bromophenyl, ~~4-chlorophenyl, alkylbenzoate,~~ alkoxyphenyl, dialkoxyphenyl, dialkylphenyl, trialkylphenyl, ~~thiophene-2-carboxylate,~~ alkylthiophenyl, trifluoromethylphenyl, acetylphenyl,

sulfamoylphenyl, biphenyl, cyclohexylphenyl, phenyloxyphenyl, dialkylaminophenyl, alkylbromophenyl, alkylchlorophenyl, alkylfluorophenyl, trifluoromethylchlorophenyl, trifluoromethylbromophenyl, ~~2,3-dihydroindeny~~, tetralinyl, trifluorophenyl, (trifluoromethyl)thiophenyl, alkoxybiphenyl, ~~indolyl, 2,3-dihydroindolyl, 1-acetyl 2,3-dihydroindolyl~~, hydroxyphenyl, hydroxyalkylphenyl, 4-amino(imino)methylphenyl, imidazolylphenyl, ~~phenylimidazolyl, phthalamido, benzophenone, aniliny~~, anisolyl, ~~quinolinonyl, phenylsulfonyl, phenylalkylsulfonyl~~, pyrimidin-5-ylphenyl, quinolidinylphenyl, furanylphenyl, ~~pyrrolidin-4-ylpyridinyl~~, and (1,4'-bipiperidin-1'-ylcarbonyl)phenyl.

114. (Currently amended) A method of any one of claims 75, 76, 78, 80, 82, or 83, wherein the variables in formula (II) are as follows:

A₁ is a substituted ~~carboecyclic aryl~~ phenyl group;

A₂ is ~~unsubstituted~~ pyridyl;

R₁ is taken together with R₂ to form a substituted C₃₋₁₄ heteroaryl group, wherein the C₃₋₁₄ heteroaryl group contains only carbon and nitrogen atoms as ring atoms; and

R₄ is C₁₋₆ alkyl;


or a pharmaceutically acceptable salt thereof.

115. (New) The method of Claim 114, wherein A₁ is selected from the group consisting of chlorophenyl, fluorophenyl, bromophenyl, iodophenyl, dihalophenyl, nitrophenyl, 4-bromophenyl, 4-chlorophenyl, alkoxyphenyl, dialkoxyphenyl, dialkylphenyl, trialkylphenyl, alkylthiophenyl, trifluoromethylphenyl, acetylphenyl, sulfamoylphenyl, biphenyl, cyclohexylphenyl, phenyloxyphenyl, dialkylaminophenyl, alkylbromophenyl, alkylchlorophenyl, alkylfluorophenyl, trifluoromethylchlorophenyl, trifluoromethylbromophenyl, trifluorophenyl,

(trifluoromethyl)thiophenyl, alkoxybiphenyl, hydroxyphenyl, hydroxyalkylphenyl, 4-amino(imino)methylphenyl and (1,4'-bipiperidin-1'-ylcarbonyl)phenyl.

116. (New) A method of any one of claims 75, 76, 78, 80, 82, or 83, wherein the variables in formula (II) are as follows:

A₁ is a substituted phenyl, pyridyl, pyrimidinyl, thiophenyl, indenyl, indolyl, isoxazolyl, indazolyl, imidazolyl, benzimidazolyl, naphthyl, 9H-fluoren-1-yl, or furanyl;



R₁ is taken together with R₂ to form substituted pyridyl, pyrimidinyl, thiazolyl, indolyl, imidazolyl, oxadiazolyl, tetrazolyl, pyrazinyl, triazolyl, thiophenyl, furanyl, quinoliny, purinyl, benzothiazolyl, benzopyridyl, or benzoimidazolyl; and

R₃ is hydrogen; and

R₄ is C₁₋₆ alkyl;

or a pharmaceutically acceptable salt thereof.

117. (New) The method of Claim 116, wherein A₁ is substituted phenyl.

118. (New) The method of Claim 117, wherein A₁ is selected from the group consisting of chlorophenyl, fluorophenyl, bromophenyl, iodophenyl, dihalophenyl, nitrophenyl, 4-bromophenyl, 4-chlorophenyl, alkoxyphenyl, dialkoxyphenyl, dialkylphenyl, trialkylphenyl, alkylthiophenyl, trifluoromethylphenyl, acetylphenyl, sulfamoylphenyl, biphenyl, cyclohexylphenyl, phenyloxyphenyl, dialkylaminophenyl, alkylbromophenyl, alkylchlorophenyl,

alkylfluorophenyl, trifluoromethylchlorophenyl, trifluoromethylbromophenyl, trifluorophenyl, (trifluoromethyl)thiophenyl, alkoxybiphenyl, hydroxyphenyl, hydroxyalkylphenyl, 4-amino(imino)methylphenyl and (1,4'-bipiperidin-1'-ylcarbonyl)phenyl.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{LLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100